TNF and inflammatory bowel disease: Anti-TNF-α biosimilars currently dominate the IBD biosimilar landscape, but as other high-efficacy treatments begin to reach patent expiry, the IBD biosimilar landscape is expanding with the approval of ustekinumab biosimilars and the development of biosimilars to vedolizumab [18,21,22,23,24,25].